Candriam S.C.A. Arrowhead Pharmaceuticals, Inc. Call Options Transaction History
Candriam S.C.A.
- $15.4 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARWR
# of Institutions
296Shares Held
88.5MCall Options Held
905KPut Options Held
387K-
Black Rock Inc. New York, NY15.3MShares$387 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.4MShares$313 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.56MShares$216 Million2.95% of portfolio
-
State Street Corp Boston, MA6.56MShares$165 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.14MShares$104 Million2.38% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.67B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...